Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Conraads, VM; Metra, M; Kamp, O; De Keulenaer, GW; Pieske, B; Zamorano, J; Vardas, PE; Böhm, M; Dei Cas, L.
Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.
EUR J HEART FAIL. 2012; 14(2): 219-225.
Doi: 10.1093/eurjhf/hfr161
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pieske Burkert Mathias
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aims We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, could favourably affect exercise capacity in patients with heart failure and preserved left ventricular ejection fraction (HFPEF). Methods and results A total of 116 subjects with HFPEF, in New York Heart Association (NYHA) functional class II-III, with left ventricular ejection fraction (LVEF) >45%, and with echo-Doppler signs of LV diastolic dysfunction, were randomized to 6 months treatment with nebivolol or placebo, following a double-blind, parallel group design. The primary endpoint of the study was the change in 6 min walk test distance (6MWTD) after 6 months. Nebivolol did not improve 6MWTD (from 420 +/- 143 to 428 +/- 141 m with nebivolol vs. from 412 +/- 123 to 446 +/- 119 m with placebo, P = 0.004 for interaction) compared with placebo, and the peak oxygen uptake also remained unchanged (peakVO(2); from 17.02 +/- 4.79 to 16.32 +/- 3.76 mL/kg/min with nebivolol vs. from 17.79 +/- 5.96 to 18.59 +/- 5.64 mL/kg/min with placebo, P = 0.63 for interaction). Resting and peak blood pressure and heart rate decreased with nebivolol. A significant correlation was found between the change in peak exercise heart rate and that in peakVO(2) (r = 0.391; P = 0.003) for the nebivolol group. Quality of life, assessed using the Minnesota Living with Heart Failure (TM) Questionnaire, and NYHA classification improved to a similar extent in both groups, whereas N-terminal pro brain natriuretic peptide (NT-pro BNP) plasma levels remained unchanged. Conclusions Compared with placebo, 6 months treatment with nebivolol did not improve exercise capacity in patients with HFPEF. Its negative chronotropic effect may have contributed to this result.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Antagonists - pharmacology Adrenergic beta-Antagonists - therapeutic use
- Aged -
- Benzopyrans - pharmacology Benzopyrans - therapeutic use
- Diastole -
- Double-Blind Method -
- Ethanolamines - pharmacology Ethanolamines - therapeutic use
- Exercise Test - drug effects
- Exercise Tolerance - drug effects
- Female -
- Humans -
- Male -
- Middle Aged -
- Stroke Volume -
- Ventricular Dysfunction, Left - drug therapy
- Ventricular Function, Left - drug effects
- Find related publications in this database (Keywords)
- Nebivolol
- Heart failure
- Heart failure with preserved ejection fraction
- Exercise capacity
- Chronotropic